- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01502137
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis
January 23, 2017 updated by: Novo Nordisk A/S
An Open, Non-randomized, Single-centre, Parallel Group Trial Investigating the Steady-state Blood Concentration Profile and Effects of Once Daily Subcutaneously Injected Recombinant Human Growth Hormone (Norditropin® SimpleXx®) in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis and in Matched Healthy Subjects
This trial is conducted in Europe.
The aim of this trial is to to compare steady-state total growth hormone (GH) exposure in haemodialysis (HD) patients with that of matched healthy subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
München, Germany, 81241
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- PATIENTS:
- Male or female, age equal to or above 18 years undergoing chronic haemodialysis
- Stable and adequate haemodialysis treatment three months prior to enrolment
- HEALTHY SUBJECTS:
- Matching an individual of the patient group by: Gender and age (± 5 years)
- Matching an individual of the patient group by weight (after dialysis, ±10%)
- Creatinine clearance above 80 ml/min
- Subjects must be in good health in accordance with their age as determined by a medical
- history, physical examination, vital signs, ECG (electrocardiogram), routine haematology and clinical chemistry
Exclusion Criteria:
- Use of cuprophane membranes
- Active malignant disease
- Diabetes
- Critical illness as defined by the need of respiratory or circulatory support
- Known or suspected allergy to the trial product
- Pregnancy, breast feeding, the intention of becoming pregnant or fertile women judged to be
- using inadequate contraceptive measures
- Blood Pressure (pre-dialysis) above 180/110
- Chronic treatment with steroids in doses above 10 mg/day prednisolone (or equivalent)
- Treated with immunosuppressive agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Healthy subjects
|
Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily.
Additional dose administered during dialysis.
In total, patients will receive 8 doses.
Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily.
Additional dose administered during dialysis.
In total, subjects will receive 7 doses.
|
|
Experimental: ESRD patients
|
Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily.
Additional dose administered during dialysis.
In total, patients will receive 8 doses.
Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily.
Additional dose administered during dialysis.
In total, subjects will receive 7 doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Growth hormone exposure at steady state
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Area under the Curve (AUC)
|
|
Cmax (maximum plasma concentration)
|
|
t½ (terminal half-life)
|
|
tmax (time to reach maximum)
|
|
IGF-I (Insulin-Like Growth Factor I)
|
|
Adverse events (AE)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion (Actual)
November 1, 2005
Study Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
December 29, 2011
First Submitted That Met QC Criteria
December 29, 2011
First Posted (Estimate)
December 30, 2011
Study Record Updates
Last Update Posted (Estimate)
January 24, 2017
Last Update Submitted That Met QC Criteria
January 23, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1630-1559
- 2005-000765-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.